文献速递心力衰竭与心肌病

核纤层蛋白病心力衰竭自然史与风险预测模型

Laminopathies: natural history and risk prediction of heart failure.
PubMed 文献 · Eur Heart J · 2026-01-01

基于法国 LMNA 全国注册研究,在 470 例成人核纤层蛋白病患者中构建严重心力衰竭事件(HF-MACE)预测模型,并在 245 例国际队列中验证。模型纳入男性、LVEF <50%、头杆域错义变异和完全性左束支传导阻滞四个独立预测因子。该模型可为成人核纤层蛋白病的早期预防管理提供依据。

要点

  • 四个独立预测因子:男性、LVEF <50%、头杆域错义变异、完全性左束支传导阻滞
  • 基线 LVEF <30% 患者 1 年 HF-MACE 发生率高达 50%,被排除在风险评分之外
  • 具有 0、1、≥2 个危险因素患者的 5 年 HF-MACE 累积发生率分别为 1.5%、5.0%、22.0%

核心结论

  • 在成人核纤层蛋白病患者中首次建立严重心力衰竭事件的预测模型,可用于早期预防管理。
  • 模型在推导队列和验证队列中均显示良好的区分度。

研究设计与样本

  • 推导队列来自法国 LMNA 全国注册研究,共纳入 470 例成人发病患者。
  • 验证队列为独立的国际队列,共 245 例患者。
  • 中位随访 7.1 年(四分位距 3.4–12.1)。

主要发现

  • 推导队列 470 例患者中,65 例在中位随访 7.1 年期间发生 HF-MACE。
  • 男性、LVEF <50%、头杆域错义变异、完全性左束支传导阻滞为独立预测因子。
  • 基线 LVEF <30% 患者被排除后,模型 C 指数在推导队列中为 0.750(95% CI 0.720–0.780),验证队列中为 0.758(95% CI 0.720–0.800)。
  • 0、1、≥2 个危险因素患者 5 年 HF-MACE 累积发生率分别为 1.5%(95% CI 0.6–3.6)、5.0%(95% CI 1.8–8.2)、22.0%(95% CI 15.6–28.4)。

关键数值与推荐

  • 主要终点 HF-MACE 定义为心力衰竭住院、心力衰竭相关死亡、机械循环支持或心脏移植。
  • 男性 HR 为 1.86(95% CI 1.060–3.290),LVEF <50% 的 HR 为 2.18(95% CI 1.080–4.400)。
  • 头杆域错义变异的 HR 为 2.91(95% CI 1.110–7.630),完全性左束支传导阻滞的 HR 为 2.99(95% CI 1.400–6.400)。
  • 基线 LVEF <30% 患者 1 年 HF-MACE 发生率为 50%。
  • 统计分析采用 Fine-Gray 竞争风险模型,报告校正风险比(aHR)及 Harrell 一致性指数(C 指数)。

临床怎么用

  • 对携带 LMNA 基因变异的成人患者,可应用该模型进行严重心力衰竭事件风险分层。
  • 基线 LVEF <30% 的患者属于高危人群,需更积极的预防和监测策略。
  • 模型确定的危险因素可帮助识别需要早期强化心力衰竭预防管理的患者。

局限性

  • 基线 LVEF <30% 的患者被排除在风险评分构建之外,该亚组需单独评估。
  • 推导队列病例来源于注册研究,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with LMNA gene variants are at high risk for dilated cardiomyopathy and heart failure (HF), but no prediction model for severe HF events exists. This study aimed to describe the incidence of severe HF events and develop a prediction model in a large cohort of patients with adult-onset laminopathies. METHODS: From a population of 660 patients enrolled in the French LMNA nationwide registry, 470 adults were included in the derivation cohort. An independent international validation cohort included 245 additional patients. Baseline characteristics at genetic testing were assessed and the cumulative incidence of the primary endpoint HF-major adverse cardiac events (HF-MACE) was calculated, defined as HF hospitalization, HF-related death, mechanical circulatory support, or heart transplantation. Predictors of HF-MACE were studied after excluding patients with left ventricular ejection fraction (LVEF) <30% at baseline using a Fine-Gray competing risk model, adjusted hazard ratio (aHR) with 95% confidence interval (CI), and Harrell's concordance (C-) index. A secondary composite endpoint, without hospitalization, was also studied. RESULTS: Among 470 patients of the derivation cohort, HF-MACE occurred in 65 over a median follow-up of 7.1 years (interquartile range: 3.4-12.1). Four independent predictors of HF-MACE were identified: male sex (aHR 1.86; 95% CI 1.060-3.290), LVEF <50% (aHR 2.18; 95% CI 1.080-4.400), missense variants in head and rod domains (aHR 2.91; 95% CI 1.110-7.630), and complete left bundle branch block (aHR 2.99; 95% CI 1.400-6.400). The C-index of the model was 0.750 (95% CI 0.720-0.780) in the derivation cohort and 0.758 (95% CI 0.720-0.800) in the validation cohort. The 5-year cumulative incidence of HF-MACE was 1.5% (95% CI 0.6-3.6), 5.0% (95% CI 1.8-8.2), and 22.0% (95% CI 15.6-28.4) among patients with 0, 1, and ≥2 risk factors, respectively. In patients with LVEF <30% at baseline, the 1-year incidence of HF-MACE was 50%, and those patients were excluded from the risk score. CONCLUSIONS: The first prediction model for severe HF events in adult laminopathies was developed, which may facilitate early and optimal preventive management. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov Unique identifier: NCT03058185.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Charron, Proukhnitzky, Ben Yaou, et al. Laminopathies: natural history and risk prediction of heart failure. Eur Heart J. 2026. PMID: 41790128. doi:10.1093/eurheartj/ehag104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。